Next generation sequencing market to surpass USD 49279.9M 2030

The technologies for rapid DNA sequencing known as next generation sequencing (NGS) can sequence millions or billions of DNA strands simultaneously, which greatly increases productivity and eliminates need for sub-cloning to fix things (Sanger sequencing of genomes). On the other hand, because the signal-to-noise ratio improves with longer reads, NGS read lengths are shorter than Sanger’s. Thanks to NGS, a wide range of mutations in many genes can be checked at once. In the case of patient exhibiting Leigh syndrome symptoms, for example, exome sequencing can be used to identify putative gene variants. In addition, it is utilized in the analysis and interpretation of sequenced data, specifically in the investigation of genes linked to the clinical condition of the patient.

The worldwide demand for next-generation sequencing is anticipated to reach US$12,870.5 Mn by the end of the year 2022, with a CAGR of 18.3% from 2017 to 2022. (2022-2030).

Increasing need for initial cancer detection and communicable diseases are anticipated to push the market of the NGS (next generation sequencing) and its growth
Early cancer detection and transmittable diseases increases the likelihood of successful treatment. The increasing incidence of cancer and other transmittable diseases like meningococcal disease, and tuberculosis etc. is one of the primary forces propelling the next generation sequencing market forward. The WHO (World Health Organization) reported in February 2022 that cancer will kill approximately 10 Mn people worldwide in the year 2020.

Growing expansions in NGS (next generation sequencing) procedures are anticipated to boost the growth of the market in the predicted period.

Next generation sequencing instruments and technologies have improved the speed, accuracy, and cost-effectiveness of DNA testing in comparison to the more traditional method of genotyping using a DNA microarray. In January of 2022, researchers at Stanford Medicine and their colleagues used a novel ultra-rapid genome sequencing approach to detect uncommon genetic disorders in about 8 hours typically. Using genome sequencing, doctors can learn about a patient’s complete genetic makeup, which includes clues to everything from their eye color to the presence of any hereditary diseases. The sequencing of a person’s genome is a crucial part of detecting patients with genetic diseases.

Global NGS (Next Generation Sequencing)– Effect of coronavirus (Covid-19) pandemic_MI
Over a hundred countries have reported cases of Covid-19 since the outbreak in December 2019, and on January 30, 2020, the WHO (World Health Organization) declared the situation a global public health emergency.

There are three primary ways in which Covid-19 can impact the economy: through direct effects on the production and demand for pharmaceuticals, medical devices and vaccines; via interruptions in distribution channels; and through monetary effects on businesses and financial markets. Saudi Arabia, China, India, the United Arab Emirates, Egypt, and others are experiencing difficulties transporting goods from one location to another as a result of nationwide lockdowns.

However, the market for NGS (next generation sequencing) worldwide benefited from the Covid-19 pandemic, as it led to more investment in R&D by industry leaders into developing methods of using next-generation sequencing to diagnose Covid-19 infections. For example, Illumina, Inc., a global leader in developing innovative array-based solutions for DNA, RNA, and protein analysis, will be the first organization to use next-generation sequence technology to conduct a diagnostic test for Covid-19 in June 2020. The Illumina COVIDSeq Test was approved by the Food and Drug Administration for the qualitative detection of SARS-CoV-2 RNA in respiratory specimens from patients who have been diagnosed with Covid-19.

Global next generation sequencing: Key developments_MI
BioQule NGS System, a computer controlled bench – top NGS library preparation solution for up to 8 samples, was released on June 6, 2022 by PerkinElmer, Inc., a global corporation focused on diagnostics, life science research, food, environmental, and industrial testing. The BioQule NGS System helps researchers create high-quality NGS libraries that consistently deliver accurate and reproducible results across a range of genomic analysis applications by combining computer controlled thermo cycling, incorporated optical quantification for quality assurance, and reliable liquid handling equipment.

By integrating the Illumina NextSeq 1000 and NextSeq 2000 sequencing systems with the GeoMx Digital Spatial Profiler, NanoString Technologies, Inc. which is a leading provider of life science tools for discovering and translational research, announced in May 2022 a seamless, cloud-based workflow that enhances the spatial data analysis experience for customers. This integrated, one-button run planning tool streamlines the process of spatially analyzing whole transcriptomes in conjunction with proteome analytes.

Global next generation sequencing: Restraint_MI
The massive amounts of data created by next-generation sequencing and the difficulty in making sense of that data are two of the main factors holding back the expansion of the global next-generation sequencing market. Even though great strides have been made to extend NGS applications from the lab to the clinic, NGS still presents enormous challenges in quality control management, data storage, processing, and explanation, which transfer time from lab to bedside needs to be lengthened.

Key players_MI
The chief companies participating in the market for next generation sequencing worldwide are Thermo Fisher Scientific Inc., Agilent Technologies, Inc, bioMérieux SA, F. Hoffmann-La Roche Ltd , QIAGEN, Illumina, Inc., Oxford Nanopore Technologies plc., BGI, PerkinElmer Genomics, and Pierian. Coherent Market Insights